Navarro-Partida Jose, Castro-Castaneda Carlos Rodrigo, Santa Cruz-Pavlovich Francisco J, Aceves-Franco Luis Abraham, Guy Tomer Ori, Santos Arturo
Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Campus Guadalajara, P.C., Zapopan 45138, Mexico.
Centro de Retina Medica y Quirurgica, S.C., Centro Medico Puerta de Hierro, P.C., Zapopan 45116, Mexico.
Pharmaceutics. 2021 May 9;13(5):678. doi: 10.3390/pharmaceutics13050678.
Effective drug delivery to intraocular tissues remains a great challenge due to complex anatomical and physiological barriers that selectively limit the entry of drugs into the eye. To overcome these challenges, frequent topical application and regular intravitreal injections are currently used to achieve the desired drug concentrations into the eye. However, the repetitive installation or recurrent injections may result in several side effects. Recent advancements in the field of nanoparticle-based drug delivery have demonstrated promising results for topical ophthalmic nanotherapies in the treatment of intraocular diseases. Studies have revealed that nanocarriers enhance the intraocular half-life and bioavailability of several therapies including proteins, peptides and genetic material. Amongst the array of nanoparticles available nowadays, lipid-based nanosystems have shown an increased efficiency and feasibility in topical formulations, making them an important target for constant and thorough research in both preclinical and clinical practice. In this review, we will cover the promising lipid-based nanocarriers used in topical ophthalmic formulations for intraocular drug delivery.
由于复杂的解剖学和生理学屏障会选择性地限制药物进入眼睛，因此实现向眼内组织的有效药物递送仍然是一项巨大挑战。为了克服这些挑战，目前通过频繁局部应用和定期玻璃体内注射来在眼内达到所需的药物浓度。然而，重复给药或反复注射可能会导致多种副作用。基于纳米颗粒的药物递送领域的最新进展已显示出局部眼科纳米疗法在治疗眼内疾病方面的良好效果。研究表明，纳米载体可提高包括蛋白质、肽和遗传物质在内的多种疗法的眼内半衰期和生物利用度。在如今可用的一系列纳米颗粒中，基于脂质的纳米系统在局部制剂中显示出更高的效率和可行性，使其成为临床前和临床实践中持续深入研究的重要对象。在本综述中，我们将介绍用于局部眼科制剂以实现眼内药物递送的有前景的基于脂质的纳米载体。
